Examining systemic steroid use in older inflammatory bowel disease patients using hurdle models: a cohort study

Table 2 Annual Utilization by IBD Drug Class

	Number of utilizers per 1000 IBD patients per year^a
Class of Agent	2006	2007	2008	2009
Systemic Steroids	303	345	336	317
Immunomodulators	48	53	50	45
antiTNFs	12	16	22	17
Nonbiologic Immunomodulators^b	42	45	37	35
Aminosalicylates	285	265	246	249
Locally administered steroids	12	11	<11^c	<11^c
Antidiarrheals	129	121	115	118

^aMid-year population used to calculate utilizers per year
^bNonbiologic immunomodulators include azathioprine, mercaptopurine, and methotrexate
^cCell size too small and requires suppression
^dThese utilization numbers were derived by dividing the number of patients who received a particular drug class during the year by the mid-year study population and multiplying by 1000.

ISSN: 2050-6511